
Natco to buy U.S. firm Dash in $18-mn deal
The Hindu
Drugmaker Natco Pharma is planning to acquire U.S. firm Dash Pharmaceuticals LLC, for a cash consideration of $18 million, through one of its subsidiaries. The acquisition, which is likely to be compl
Drugmaker Natco Pharma is planning to acquire U.S. firm Dash Pharmaceuticals LLC, for a cash consideration of $18 million, through one of its subsidiaries.
The acquisition, which is likely to be completed by January, will provide a front-end to engage with its customers directly in the U.S., the largest pharmaceutical market in the world, Natco Pharma said on Tuesday.
In a filing with the stock exchange, following a meeting of the Board, Natco said it proposed to enter into an agreement to acquire 100% stake in Dash Pharmaceuticals. The transaction will be subject to satisfactory completion of due diligence, execution of definitive agreements and compliance with statutory requirements.

Insurance penetration and density are often misunderstood and do not reveal how many families are insured or whether they would be financially secure if the main earning member were to die. The real issue is not reach but adequacy, as households may have life insurance but not enough cover to replace lost income, leaving them financially vulnerable.












